Stocks and Investing
Stocks and Investing
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thomas Shrader Maintained (BCAB) at Strong Buy with Decreased Target to $13 on, Mar 28th, 2023
Thomas Shrader of BTIG, Maintained "BioAtla, Inc." (BCAB) at Strong Buy with Decreased Target from $68 to $13 on, Mar 28th, 2023.
Thomas has made no other calls on BCAB in the last 4 months.
There are 4 other peers that have a rating on BCAB. Out of the 4 peers that are also analyzing BCAB, 1 agrees with Thomas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Reiterated at Hold and Held Target at $8 on, Friday, March 24th, 2023
These are the ratings of the 3 analyists that currently disagree with Thomas
- Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $12 on, Monday, March 27th, 2023
- Tony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $25 on, Friday, March 24th, 2023
- Arthur He of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $17 on, Friday, March 24th, 2023
Contributing Sources